1. Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. (1st September 2017) Authors: Blauvelt, A.; Reich, K.; Warren, R.B.; Szepietowski, J.C.; Sigurgeirsson, B.; Tyring, S. K.; Messina, I.; Bhosekar, V.; Oliver, J.; Papavassilis, C.; Frueh, J.; Langley, R.G.B. Journal: British journal of dermatology Issue: Volume 177:Number 3(2017) Page Start: 879 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. (9th August 2017) Authors: Blauvelt, A.; Reich, K.; Warren, R.B.; Szepietowski, J.C.; Sigurgeirsson, B.; Tyring, S. K.; Messina, I.; Bhosekar, V.; Oliver, J.; Papavassilis, C.; Frueh, J.; Langley, R.G.B. Journal: British journal of dermatology Issue: Volume 177:Number 3(2017) Page Start: 879 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Secukinumab treatment in new‐onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter STEPIn study. (15th July 2018) Authors: Iversen, L.; Eidsmo, L.; Austad, J.; de Rie, M.; Osmancevic, A.; Skov, L.; Talme, T.; Bachmann, I.; van de Kerkhof, P.; Stahle, M.; Banerjee, R.; Oliver, J.; Fasth, A.E.R.; Frueh, J. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 11(2018) Page Start: 1930 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗